alendronate and triiodothyronine

alendronate has been researched along with triiodothyronine in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (25.00)18.2507
2000's1 (25.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Affinito, P; Arlotta, F; Cascone, E; Di Carlo, C; Lupoli, G; Nappi, C; Nuzzo, V; Vitale, G; Vollery, M1
Bentz, B; Bray, GA; Browndyke, J; Gouvier, WD; Hammer, JH; Hilsabeck, RC; Lovejoy, JC; Pinkston, JB; Santa Maria, MP; Smiroldo, B; Smith, SR1

Reviews

1 review(s) available for alendronate and triiodothyronine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

1 trial(s) available for alendronate and triiodothyronine

ArticleYear
Neuropsychological and emotional changes during simulated microgravity: effects of triiodothyronine alendronate, and testosterone.
    Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists, 2004, Volume: 19, Issue:2

    Topics: Adult; Alendronate; Cognition; Emotions; Female; Head-Down Tilt; Humans; Male; Middle Aged; Neuropsychological Tests; Testosterone; Time Factors; Triiodothyronine; Weightlessness Countermeasures; Weightlessness Simulation

2004

Other Studies

2 other study(ies) available for alendronate and triiodothyronine

ArticleYear
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
Effects of alendronate on bone loss in pre- and postmenopausal hyperthyroid women treated with methimazole.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 1996, Volume: 10, Issue:5

    Topics: Adult; Alendronate; Bone Density; Female; Humans; Hyperthyroidism; Methimazole; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Thyrotropin; Thyroxine; Triiodothyronine

1996